Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.61 |
| ▸ | CFTR | P13569 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28912058 | 1.00 | NR1D1 (0.61) | NR1D1CFTRTSHRBCL2BAD | |
| SCHEMBL28566774 | 0.88 | CFTR (0.59) | NR1D1CFTRPDE4BPDE4DLMNA | |
| SCHEMBL29409307 | 0.88 | CFTR (0.59) | NR1D1CFTRPDE4BPDE4DLMNA | |
| SCHEMBL37599856 | 0.88 | CFTR (0.59) | NR1D1CFTRPDE4BPDE4DLMNA | |
| SCHEMBL29409298 | 0.86 | NR1D1 (0.62) | NR1D1CFTRBCL2BADPDE4B | |
| SCHEMBL28550513 | 0.86 | NR1D1 (0.62) | NR1D1CFTRBCL2BADPDE4B | |
| SCHEMBL28555813 | 0.83 | NR1D1 (0.64) | NR1D1CFTRBCL2BADPDE4B | |
| SCHEMBL29409302 | 0.83 | NR1D1 (0.64) | NR1D1CFTRBCL2BADPDE4B | |
| SCHEMBL29409296 | 0.83 | CFTR (0.57) | CFTRLMNAPKMHTR1AHTR7 | |
| SCHEMBL28560316 | 0.83 | CFTR (0.57) | CFTRLMNAPKMHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112752837-B | Natural killer cells | 帝国理工学院创新有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12377119-B2 | Natural killer cells | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20220073880-A1 | NATURAL KILLER CELLS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073880-A1 | NATURAL KILLER CELLS | PBK, IKZF3, IKZF1 | NR1D1 2299/4885CFTR 1048/4885TSHR 3744/4885 |
| US-12377119-B2 | Natural killer cells | PBK, IKZF3, IKZF1 | NR1D1 2299/4885CFTR 1048/4885TSHR 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.